1 hr ago
Hospital stocks face drug-pricing scrutiny as investors weigh risks
The Supreme Court questioned why some hospitals may charge much more for medicines than retailers do.
One example involved a cancer medicine costing Rs 2,700 for retailers but Rs 27,000 for a hospital patient.
This made investors worry that hospitals could earn less money from their pharmacies.
Hospital shares fell for a second day.
One analyst said pharmacies can provide 10-25% of a hospital’s revenue and profits.
Another analyst expects a possible 2-4% reduction in EBITDA if rules are limited.
A wider price cap could hurt earnings more.
The court has not made a final decision, so investors are waiting for clearer rules.
The Supreme Court questioned steep mark-ups on cancer drugs, including a reported Rs 27,000 hospital price versus Rs 2,700 for retailers.
Investors are concerned that future regulation could reduce hospital pharmacy income and overall profitability.
Pharmacy operations may contribute about 10-25% of hospital revenue and profitability, according to SBI Securities’ Sunny Agrawal.
Mirae Asset Sharekhan estimates a potential 2-4% EBITDA reduction in its base case, while a broader 16% cap could have a larger impact.
Analysts say the court’s comments are not a final order, and investors should await clarity on which medicines and margins might be regulated.
- Who
- The Supreme Court, hospital companies, investors, and analysts Sunny Agrawal of SBI Securities and Thomas V Abraham of Mirae Asset Sharekhan.
- What
- The Supreme Court questioned hospital medicine mark-ups, prompting a sell-off in hospital stocks and debate over whether to buy the decline or remain cautious.
- Where
- The issue concerns hospital pharmacies and hospital stocks traded on Dalal Street.
- When
- The concerns and market reaction occurred this week, with hospital shares falling for a second consecutive day.
- Why
- Investors fear that future limits on medicine mark-ups could reduce pharmacy income and hospital profitability.
Stay cautious
Consider limited-impact opportunities
Near-term investment approach
Stay cautious
Sunny Agrawal recommends remaining on the sidelines until the regulatory framework is clearer because pharmacy margins could come under pressure.
Consider limited-impact opportunities
Thomas V Abraham indicates the impact may be limited if any cap applies mainly to critical, life-saving drugs, though he does not treat the court’s comments as a final decision.
Potential earnings effect
Stay cautious
A broader restriction on medicine margins could materially reduce hospital profitability because pharmacies contribute significantly to revenue and profits.
Consider limited-impact opportunities
In the base case, the market expects a 2-4% EBITDA reduction, suggesting a potentially manageable impact if regulation is narrowly designed.
Scope of possible regulation
Stay cautious
A broad cap on hospital pharmacy margins, including a possible 16% limit over the price to retailer, could create a substantially larger earnings impact.
Consider limited-impact opportunities
Limiting measures to selected critical drugs could balance affordability with hospital operating efficiency and expansion needs.
Key facts
- Example price difference
- A cancer drug was cited as costing Rs 27,000 at a hospital versus Rs 2,700 for retailers.
- Pharmacy contribution
- Hospital pharmacies may account for about 10-25% of hospital revenue and profitability.
- Base-case earnings impact
- Mirae Asset Sharekhan expects a possible 2-4% reduction in EBITDA from current estimates.
- Broader cap scenario
- A 16% cap over the price to retailer could create a substantially larger impact.
- Regulatory status
- The Supreme Court’s comments are observations, not a final regulatory order or verdict.
- Reporting limitation
- Hospitals generally do not disclose pharmacy revenue separately, making company-level impacts difficult to estimate.
- Key investor focus
- The impact will depend on whether regulation covers selected critical drugs or hospital pharmacy margins more broadly.
Quotes
Thomas V Abraham
Research Analyst at Mirae Asset Sharekhan
“On the proposed regulatory changes, I believe it is prudent to remain on the sidelines for now. Hospital pharmacies can contribute around 10–25% of a hospital’s revenue and profitability. Any clampdown on the margins that can be charged on pharmacy business could therefore put pressure on hospital profitability. So, it would be better to wait for greater clarity on the regulatory framework before taking a view.”
financialexpress.com
“The questions raised by the Supreme Court so far relate largely to critical, life-saving drugs. These are observations rather than a verdict, and the matter will be deliberated further. We expect any capping, if imposed, to be limited to critical drugs in the current scenario.”
financialexpress.com
Sources
Related news
Jefferies Sees 22-46% Upside in Major Hospital Stocks
Brokerages See Hospital Stocks Rising Despite Supreme Court Scrutiny
Supreme Court Questions Steep Mark-Ups on Essential Medicines
Supreme Court Slams Tenfold Cancer Drug Markups by Hospitals
Max Healthcare Plans ₹6,000 Crore Expansion Amid Margin Debate
Karnataka Seeks Centre Action Over Hospital Drug Price Gaps
Pace Digitek Shares Jump 11% as BESS Order Highlights Growth
Eight Indian Stocks Show Inconsistent Dividend Payouts
KPI Green Energy Expands Wind Portfolio Through ₹2,410 Crore Deal
Nifty Bounces From 200 WMA, Trims Losses on Expiry Day
